Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Ultrasis PLC (ULT)

  Print      Mail a friend       Annual reports

Tuesday 25 November, 2008

Ultrasis PLC

Extension of contract

RNS Number : 8009I
Ultrasis PLC
25 November 2008

November 25 2008 

Ultrasis plc

Two-year contract extension in Hertfordshire PCTs

Ultrasis plc, the provider of interactive healthcare and associated services, is pleased to announce that East and North Hertfordshire PCT and West Hertfordshire PCT have extended their Beating the Blues contract for a further two years and also increased their compliance level with NICE guidance to 50%.

This two-year contract will have an initial value in excess of £230,000. 

Nigel Brabbins, Ultrasis Chief Executive, said: 'The current contract with the PCTs ends in March 2009 but they have agreed to renew early and increase availability, clearly demonstrating commissioner confidence in the value of having Beating the Blues as a strand of their Improving Access to Psychological Therapies (IAPT) program.

 'We have invested company time and resource in building a solid partnership with the NHS and are now seeing significant momentum develop as commissioners begin to see the positive benefits of working with the Ultrasis team and its products.'


Editors Notes:

Ultrasis plc is a healthcare company with core expertise in health, psychology, software development and programme management. The Company delivers computerised healthcare products to the NHS, the corporate sector and other healthcare providers in the UK and internationally. 

Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is the world leader in this field. The products help people tackle stress, anxiety and depression, and a full spectrum of related chronic conditions. 

Beating the Blues is an eight-week, web-based treatment programme for depression based on Cognitive Behavioural Therapy. Following a rigorous examination by the National Institute for Health and Clinical Excellence (NICE), 'Beating the Blues' was approved by NICE in February 2006 for use in the National Health Service. 

On 28 March 2007 the Secretary of State for Health announced a framework agreement for the use of cCBT in the NHS and approved 'Beating the Blues', saying: 'Computer-based therapy for milder, but more common mental health conditions such as depression and anxiety should be made available to any patients in England who could benefit from it from April 2007.'

For further information please contact:

Nigel Brabbins

[email protected]
Telephone: +44 (0) 20 7566 3900

Fax: +44 (0) 20 7253 5313

Geoff Nash

Nominated Adviser and Joint Broker

Telephone: +44 (0) 20 7600 1658

John Webb
Marshall Securities

Joint Broker

+44 (0) 207 490 3788

Karen White/Sarah Rice

JBP Public Relations

E-Mail: [email protected][email protected]

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t